SLS BIO Co., Ltd (KOSDAQ:246250)
South Korea · Delayed Price · Currency is KRW 1,969.00
+85.00 (4.51%)
At close: Jun 9, 2025
SLS BIO Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2015 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '15 Dec 31, 2015 |
Operating Revenue | 3,187 | 3,984 | 8,371 | 9,023 | 10,752 | 6,214 |
Other Revenue | 0 | 0 | - | - | -0 | 0 |
| 3,187 | 3,984 | 8,371 | 9,023 | 10,752 | 6,214 | |
Revenue Growth (YoY) | -60.55% | -52.41% | -7.23% | -16.08% | 73.02% | 6.75% |
Cost of Revenue | 5,939 | 5,921 | 6,102 | 5,912 | 6,542 | 4,851 |
Gross Profit | -2,752 | -1,937 | 2,269 | 3,111 | 4,210 | 1,363 |
Selling, General & Admin | 1,442 | 1,450 | 1,195 | 1,294 | 1,119 | 416.94 |
Research & Development | 521.55 | 596.11 | 591 | 533.56 | 503.7 | 303.66 |
Amortization of Goodwill & Intangibles | 23.53 | 24.26 | 24.04 | 20.08 | 17.53 | 20.64 |
Operating Expenses | 2,084 | 2,168 | 1,981 | 2,080 | 1,786 | 840.46 |
Operating Income | -4,836 | -4,105 | 287.62 | 1,031 | 2,424 | 522.53 |
Interest Expense | -61.53 | -66.57 | -83.92 | -100.85 | -135.99 | -336.36 |
Interest & Investment Income | 136.97 | 174.72 | 282.53 | 166.85 | 122.76 | 9.12 |
Currency Exchange Gain (Loss) | -0 | -0.24 | -1.87 | -0.21 | -0.07 | - |
Other Non Operating Income (Expenses) | -1,357 | -1,382 | -130.24 | -0.38 | 10.51 | -1.52 |
EBT Excluding Unusual Items | -6,118 | -5,380 | 354.11 | 1,096 | 2,421 | 193.76 |
Gain (Loss) on Sale of Investments | - | - | - | -39.06 | -236.35 | - |
Gain (Loss) on Sale of Assets | - | 0.14 | -0 | -0.01 | 40.3 | 4 |
Pretax Income | -6,118 | -5,380 | 354.11 | 1,057 | 2,225 | 197.76 |
Income Tax Expense | -473.79 | -475.94 | 18.49 | -376.67 | -601.13 | -6.71 |
Net Income | -5,644 | -4,904 | 335.63 | 1,434 | 2,826 | 204.47 |
Net Income to Common | -5,644 | -4,904 | 335.63 | 1,434 | 2,826 | 204.47 |
Net Income Growth | - | - | -76.60% | -49.26% | 1282.14% | -36.46% |
Shares Outstanding (Basic) | 15 | 15 | 15 | 14 | 7 | 5 |
Shares Outstanding (Diluted) | 15 | 15 | 15 | 14 | 7 | 5 |
Shares Change (YoY) | -15.34% | -1.36% | 8.51% | 104.97% | 37.54% | 14.68% |
EPS (Basic) | -382.48 | -325.88 | 22.00 | 102.00 | 412.00 | 41.00 |
EPS (Diluted) | -382.48 | -325.88 | 22.00 | 102.00 | 412.00 | 41.00 |
EPS Growth | - | - | -78.43% | -75.24% | 904.88% | -44.59% |
Free Cash Flow | -4,736 | -3,709 | 269.92 | 2,162 | 3,315 | 97.66 |
Free Cash Flow Per Share | -320.98 | -246.45 | 17.69 | 153.75 | 483.26 | 19.58 |
Gross Margin | -86.35% | -48.63% | 27.10% | 34.48% | 39.16% | 21.93% |
Operating Margin | -151.75% | -103.05% | 3.44% | 11.43% | 22.54% | 8.41% |
Profit Margin | -177.10% | -123.09% | 4.01% | 15.89% | 26.28% | 3.29% |
Free Cash Flow Margin | -148.62% | -93.09% | 3.22% | 23.96% | 30.83% | 1.57% |
EBITDA | -3,570 | -2,822 | 1,624 | 2,309 | 3,727 | 1,139 |
EBITDA Margin | -112.02% | -70.84% | 19.40% | 25.59% | 34.66% | 18.32% |
D&A For EBITDA | 1,266 | 1,283 | 1,336 | 1,278 | 1,303 | 616.03 |
EBIT | -4,836 | -4,105 | 287.62 | 1,031 | 2,424 | 522.53 |
EBIT Margin | -151.75% | -103.05% | 3.44% | 11.43% | 22.54% | 8.41% |
Effective Tax Rate | - | - | 5.22% | - | - | - |